JPRN-UMIN000008940已完成2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Ninjin-yoei-to for lung cancer patients resistant to standard therapies . - Phase II study of personalized peptide vaccination in combination with Ninjin-yoei-to for lung cancer patients.
Kurume University Cancer Vaccine Center0 个研究点目标入组 80 人开始时间: 2012年9月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1)Patients with severe underlying diseases/conditions (active and severe infectious diseases, circulatory diseases, respiratory diseases, ranal diseases, immunodeficiencies, disturbance of coagulation, et al). 2)Active double cancer(synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ(lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 3)Patients with the past history of severe allergic reactions. 4)patients with pulmonary disorder (idiopathic pulmonary fibrosis,interstitial pneumonia,pneumoconiosis,radiation pneumonia,drug-induced pneumonia). 5)(Females) Pregnant or nursing patients. Patients desiring future fertility. (Males) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination. 6)Patients who are judged inappropriate for entry to this clinical trial by doctors. 7)Patients who has taken Ninjin-yoei-to.
研究者
相似试验
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.colorectal cancerJPRN-UMIN000008126Kurume University Cancer Vaccine Center60
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Juzen-taiho-to for gastric cancer patients resistant to standard therapies .gastric cancerJPRN-UMIN000008827Kurume University Cancer Vaccine Center60
已完成
2 期
Randomized Phase II clinical trial of personalized peptide vaccination for HCV positive patients with advanced liver cancer.liver cancerJPRN-UMIN000003520Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division84
已完成
2 期
Randomized Phase II clinical trial of personalized peptide vaccination for patients with advanced (stage IIIB/IV) or recurrence non-small cell lung cancer who had chemotheraphy of 1 or 2 regimen, to evaluate the progression free survial of docetaxel plus placebo versus docetaxel plus pesonalized pepitide vaccine.non-small cell lung cancerJPRN-UMIN000003521Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division64
已完成
2 期
A phase II randomized clinical trial of personalized peptide vaccination in combination with Japanese herbal medicines for castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000010290Kurume University School of medicine, Department of Immunology and Immunotherapy70